Literature DB >> 35169258

First glimpses into the mechanisms of Long COVID.

Alexandra Flemming1.   

Abstract

Entities:  

Year:  2022        PMID: 35169258      PMCID: PMC8853331          DOI: 10.1038/s41577-022-00691-7

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


× No keyword cloud information.
Post-acute sequelae of COVID-19 (PASC), sometimes referred to as ‘Long COVID’, are observed in 30–70% of individuals post-SARS-CoV-2 infection. These can include loss of sense of smell, memory loss, fatigue, shortness of breath, gastrointestinal (GI) distress and other symptoms. Autoimmune processes and unresolved viral fragments have been proposed as causative, but experimental validation for these hypotheses is lacking. Now, a longitudinal multi-omic study of >300 patients by Su et al. reveals that some factors present at disease onset, such as pre-existing type 2 diabetes, latent EBV reactivation, circulating SARS-CoV-2 RNA fragments as well as specific autoantibodies, associate with specific PASC. The authors identified four different immune endotypes at 2–3 months post disease onset that differentially associate with PASC. Interestingly, they find that bystander activation of CMV-specific T cells during acute disease is associated with GI PASC. A second study by Vijayakumar et al. shows persistent immunological and proteomic abnormalities in the lungs of patients with ongoing respiratory symptoms after COVID-19, with continuing activation of CD8+ T cells and elevated levels of proteins associated with apoptosis, tissue repair and epithelial injury.
  2 in total

1.  Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.

Authors:  Bavithra Vijayakumar; Karim Boustani; Patricia P Ogger; Artemis Papadaki; James Tonkin; Christopher M Orton; Poonam Ghai; Kornelija Suveizdyte; Richard J Hewitt; Sujal R Desai; Anand Devaraj; Robert J Snelgrove; Philip L Molyneaux; Justin L Garner; James E Peters; Pallav L Shah; Clare M Lloyd; James A Harker
Journal:  Immunity       Date:  2022-01-26       Impact factor: 43.474

2.  Multiple early factors anticipate post-acute COVID-19 sequelae.

Authors:  Yapeng Su; Dan Yuan; Daniel G Chen; Rachel H Ng; Kai Wang; Jongchan Choi; Sarah Li; Sunga Hong; Rongyu Zhang; Jingyi Xie; Sergey A Kornilov; Kelsey Scherler; Ana Jimena Pavlovitch-Bedzyk; Shen Dong; Christopher Lausted; Inyoul Lee; Shannon Fallen; Chengzhen L Dai; Priyanka Baloni; Brett Smith; Venkata R Duvvuri; Kristin G Anderson; Jing Li; Fan Yang; Caroline J Duncombe; Denise J McCulloch; Clifford Rostomily; Pamela Troisch; Jing Zhou; Sean Mackay; Quinn DeGottardi; Damon H May; Ruth Taniguchi; Rachel M Gittelman; Mark Klinger; Thomas M Snyder; Ryan Roper; Gladys Wojciechowska; Kim Murray; Rick Edmark; Simon Evans; Lesley Jones; Yong Zhou; Lee Rowen; Rachel Liu; William Chour; Heather A Algren; William R Berrington; Julie A Wallick; Rebecca A Cochran; Mary E Micikas; Terri Wrin; Christos J Petropoulos; Hunter R Cole; Trevan D Fischer; Wei Wei; Dave S B Hoon; Nathan D Price; Naeha Subramanian; Joshua A Hill; Jennifer Hadlock; Andrew T Magis; Antoni Ribas; Lewis L Lanier; Scott D Boyd; Jeffrey A Bluestone; Helen Chu; Leroy Hood; Raphael Gottardo; Philip D Greenberg; Mark M Davis; Jason D Goldman; James R Heath
Journal:  Cell       Date:  2022-01-25       Impact factor: 66.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.